If you have been reading about angiotensin IV and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-04. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
=== Metal and alloys === Bismuth is used in alloys with other metals such as tin and lead. Wood's metal, an alloy of bismuth, lead, tin, and cadmium, is used in automatic sprinkler systems for fires. It forms the largest part (50%) of Rose's metal, a fusible alloy, which also contains 25–28% lead and 22–25% tin. It was also used to make bismuth bronze, which was used during the Bronze Age, having been found in Inca knives at Machu Picchu.
=== Absorption and distribution === Oral bioavailability of trimebutine is nearly 100% for the maleate salt. Maximum serum concentration (Cmax) is achieved after 30 minutes for 100 mg dose and 0.88 h for 200 mg dose. The level of serum albumin binding is minimal. Half-life (t1/2) of 200 mg timebutine maleate is equal to 2.77 h.
In 2014, the Equality Tribunal ruled in favor of Dr Micheline Sheehy Skeffington, granddaughter of the famous Irish feminist couple Hannah Sheehy Skeffington and Francis Sheehy Skeffington, who claimed she had been discriminated against on the grounds of gender during 2009. The university "unreservedly" accepted the decision that the "hiring process was flawed". In 2015 with "widespread concern" among staff, mandatory unconscious bias training was introduced for senior staff, including heads of school and interview boards. In 2017 Dr Elizabeth Tilley was deemed to have exceeded qualifications for senior lectureship following a Labour Court hearing and promoted. In 2017, the gender ratio of senior lecturers in the university was 60:40 in favour of men. The ratio of professorships, the most senior academic grade, was 87:13 in favor of men. In 2018 the university achieved bronze status in the Athena SWAN recognises a commitment to advancing gender equality in higher education and research careers. In 2018 a further four female lecturers who had also applied for promotion in 2009 were promoted having settled their cases "amicably". The university launched its Strategic Plan "Shared Vision, Shaped By Values" (for the period 2020–2025) in 2020. Also in 2020, the university was awarded €4 million from the EU's Horizon 2020 Research and Innovation programme to support its Solar2chem project. In April 2022, it was announced that NUI Galway would be renamed "Ollscoil na Gaillimhe – University of Galway" in summer 2022, amid confusion over its proper title.
Sources: en.wikipedia.org
The aspartate pathway is an amino acid metabolic pathway present in bacteria and plants that deal with converting aspartate to other amino acids through a series of reactions and intermediates. L-Aspartate-4-semialdehyde serves as one of the first intermediates in the pathway and as an important step of differentiation in the pathway. L-Aspartate-4-semialdehyde is synthesized by the enzyme aspartate semialdehyde dehydrogenase, which catalyzes the following reversible chemical reaction:
After the discovery of the hydrogen bonded A:T and C:G pairs, Watson and Crick soon had their anti-parallel, double helical model of DNA, with the hydrogen bonds at the core of the helix providing a way to "unzip" the two complementary strands for easy replication: the last key requirement for a likely model of the genetic molecule. As important as Crick's contributions to the discovery of the double helical DNA model were, he stated that without the chance to collaborate with Watson, he would not have found the structure by himself. Crick did tentatively attempt to perform some experiments on nucleotide base pairing, but he was more of a theoretical biologist than an experimental biologist. There was another near-discovery of the base pairing rules in early 1952. Crick had started to think about interactions between the bases. He asked John Griffith to try to calculate attractive interactions between the DNA bases from chemical principles and quantum mechanics. Griffith's best guess was that A:T and G:C were attractive pairs. At that time, Crick was not aware of Chargaff's rules and he made little of Griffith's calculations, although it did start him thinking about complementary replication. Identification of the correct base-pairing rules (A-T, G-C) was achieved by Watson "playing" with cardboard cut-out models of the nucleotide bases, much in the manner that Linus Pauling had discovered the protein alpha helix a few years earlier.
The developers said they had to drop some features from the mod due to limitations of the Half-Life engine. PC Zone gave a rating of 71% for the LAN-only version and a rating of 72% for the online-compatible version, saying the online component is "very weak" and LAN is still the preferred way to play. PC Action called it a challenging and fun mod. Lambda Arena – A version of the Quake series mod Rocket Arena, released in 1999. It is mainly for one versus one matches but the mod supports teamplay up to four players. CNET Gamecenter placed it on its list of top 10 Half-Life mods, writing: "Lambda Arena has a great American Gladiators feel, with gaudy but functional arenas." Master Sword – A cooperative fantasy role-playing total conversion mod. During character creation, the player has the option to select a race, which can be either human, dwarf, or elf. The available classes include wizard, archer, and rogue. Incite PC Games gave the mod a score of seven out of ten. The mod received an expansion titled Master Sword: Continued. PC Action gave the expansion a "good" rating. Natural Selection – A mod in which two teams (humans and aliens) fight against each other. Its utilizes a mixture of first-person shooter and real-time strategy gameplay. It gained a standalone successor, Natural Selection 2. The Opera – Released on July 9, 2001. The gameplay features diving, rolling, and dual wielding that is described as "gun ballet". The game features minimal heads-up display (HUD) with no ammo, health or armour displayed. The mod was in production for two years.
Sources: en.wikipedia.org
=== Good gasoline yields === There are three types of crude oil, light, medium and heavy, according to its density. For gasoline blends, composites which are lighter hydrocarbons are used. Molecular weights of these hydrocarbons are lower than heptane. Since most of Nigerian crudes are either light or medium sweet, creating plentiful amount of diesel, they are more costly than sour crudes. Gasoline is produced from processed crude oil and it is highly valued petroleum products. Therefore, to have maximized profit, refiners seek to boost gasoline yields.
== See also == 2015 state visit by Xi Jinping to the United States APEC China 2026 China–United States relations List of international presidential trips made by Donald Trump 2026 visit by Vladimir Putin to China
Fenn shared the 2002 Nobel Prize in Chemistry with Koichi Tanaka and Kurt Wüthrich "for the development of methods for identification and structure analyses of biological macromolecules." Fenn and Tanaka split half of the award for their work in developing ionization techniques for using mass spectrometry to analyze large biological molecules. Wüthrich was honored for his work in developing nuclear magnetic resonance techniques to analyze similar molecules in solution. Fenn was honored largely for his contributions to the development of electrospray ionization, which made the analysis of large molecules by mass spectrometry feasible. Fenn's Nobel lecture after being presented with the award was entitled "Electrospray Wings for Molecular Elephants." He was surprised by his selection as a Nobel winner, saying "It's like winning the lottery, I'm still in shock." At the time of his award, Fenn was working at Virginia Commonwealth University.
A music video directed by Adam Mason was released on November 1, 2018, and continued the storyline from the music video of "The One You Know". In June 2018, William DuVall said in an interview with Swedish website Rocksverige that the music video for "The One You Know" is the first chapter of what the band is hoping will be visuals for all ten songs from the album Rainier Fog, and in addition to that, will be a companion piece to the film that director Adam Mason was shooting. On August 20, 2018, the baseball team Seattle Mariners hosted a special "Alice in Chains Night" at the Safeco Field in Seattle to promote Rainier Fog, with the team offering the fans a package that included a Safeco Field terrace club ticket, access to a pre-game listening party of the album, an Alice in Chains T-shirt and a Rainier Fog CD. Jerry Cantrell also threw out the ceremonial first pitch and delivered a strike before the Seattle Mariners vs. Houston Astros game. To mark the launch of the album, on August 21, 2018, Alice in Chains performed an acoustic set at the top of Seattle's Space Needle and debuted the song "Fly". Alice in Chains were the first band to perform on the Space Needle's new "Loupe" glass floor, the world's first and only revolving glass floor 500 feet high. The concert was exclusive for an audience of SiriusXM subscribers. SiriusXM broadcast the concert on their channel Lithium on August 31, 2018.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.